<DOC>
	<DOCNO>NCT00335647</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluphenazine , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase I/II trial study side effect best dose fluphenazine see well work treat patient refractory advanced multiple myeloma .</brief_summary>
	<brief_title>Fluphenazine Treating Patients With Refractory Advanced Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety high-dose fluphenazine hydrochloride patient refractory advanced multiple myeloma . - Determine pharmacological property drug . - Determine effectiveness drug patient . OUTLINE : This open-label , dose-escalation study . Patients receive high-dose fluphenazine hydrochloride IV 3 time day 1 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . Cohorts patient receive escalate dos fluphenazine hydrochloride maximum tolerate dose determine . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Fluphenazine</mesh_term>
	<mesh_term>Fluphenazine depot</mesh_term>
	<mesh_term>Fluphenazine enanthate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm multiple myeloma Advanced disease Must refractory ≥ 2 different method standard treatment Measurable disease , define serum paraprotein ≥ 1g/L urine light chain ≥ 200 mg/24 hour No brain involvement leptomeningeal disease No spinal cord compression unless follow criterion meet : Patient undergone prior surgery radiotherapy Neurological finding ≤ grade 1 Patient steroid spinal cord edema stable regimen ≤ 10 mg/day prednisone equivalent PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 ( ECOG PS 3 allow related skeletal lesion ) Life expectancy ≥ 12 week Absolute granulocyte count ≥ 1,000/mm^3* Platelet count ≥ 50,000/mm^3* Hemoglobin ≥ 8.0 g/dL* ( transfusion within past 7 day ) AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2 time ULN Creatinine clearance ≥ 30 mL/min LVEF ≥ 40 % QTc &lt; 450 msec No evidence dysrhythmias EKG Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No congestive heart failure No angina pectoris No cardiac arrhythmia No uncontrolled hypertension , define systolic blood pressure ( BP ) &gt; 180 mm Hg and/or diastolic BP &gt; 105 mm Hg No myocardial infarction within past year No active infection No HIV , hepatitis B , hepatitis C infection No history psychosis No history subcortical brain damage No hypersensitivity fluphenazine hydrochloride phenothiazines No history seizures extrapyramidal symptom No serious illness medical condition No malignancy within past 5 year except adequately treat nonmelanoma skin cancer carcinoma situ cervix NOTE : *Patients value outside range due infiltration myeloma may allow discretion investigator PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 21 day since prior chemotherapy , immunotherapy , radiotherapy At least 21 day since prior concurrent systemic steroid Patients take chronically administer steroid ≥ 1 month dose ≤ 10 mg/day prednisone equivalent eligible At least 28 day since prior investigational agent At least 6 week since prior selective serotonin reuptake inhibitor ( SSRIs ) ( washout period equivalent 5 time terminal elimination halflife require tricyclic antidepressant norepinephrine reuptake inhibitor ) No concurrent SSRIs , tricyclic antidepressant , norepinephrine reuptake inhibitor No concurrent dialysis therapy No concurrent hematopoietic growth factor except epoetin alfa Treatment hematopoietic growth factor may start study patient develop progressive cytopenia No concurrent anticholinergic antipsychotics No concurrent antiseizure drug except Neurontin treatment neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
</DOC>